Literature DB >> 7518392

Haematological improvement by long-term administration of recombinant human granulocyte-colony stimulating factor and recombinant human erythropoietin in a patient with severe aplastic anaemia.

J Nawata1, Y Toyoda, H Nisihira, K Honda, H Kigasawa, T Nagao.   

Abstract

A 6-year-old girl with post-hepatitic severe aplastic anaemia was referred to our hospital. Haematological examination showed a haemoglobin level of 5.2 g/dl, platelet count of 8,000/microliters, and white blood cell count of 130/microliters with 17% neutrophils. She was treated with recombinant human granulocyte-colony stimulating factor (15 micrograms/kg/day i.v.) and cyclosporin A (6 mg/kg/day p.o.). The absolute neutrophil count gradually increased, but Hb and platelets were not improved. The intravenous administration of recombinant human erythropoietin (100 U/kg three times a week) was started, and the reticulocyte count reached 20,000/microliters on day 12. The platelets increased to 81,000/microliters after 16 months of combined administration of recombinant human granulocyte-colony stimulating factor, recombinant human erythropoietin and cyclosporin A. After 20 months of combined administration, the haematological results were: Hb, 13.1 g/dl; platelets 80,000/microliters; WBC, 9500/microliters with 40% neutrophils. After recombinant human granulocyte-colony stimulating factor treatment, the myeloid elements of the bone marrow and the number of granulocyte-macrophage colony forming units increased. Bone marrow erythropoiesis and erythroid colonies also increased after recombinant human erythropoietin administration. The clinical course suggested a beneficial effect of haemopoietic growth factors and cyclosporin A in post-hepatitic aplastic anaemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518392     DOI: 10.1007/bf01956411

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  6 in total

1.  Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor (rhG-CSF) and erythropoietin (rhEpo) in severe aplastic anaemia.

Authors:  M Bessho; A Toyoda; Y Itoh; T Sakata; N Kawai; I Jinnai; M Saito; K Hirashima
Journal:  Br J Haematol       Date:  1992-03       Impact factor: 6.998

2.  Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia.

Authors:  E Gluckman; H Esperou-Bourdeau; A Baruchel; M Boogaerts; J Briere; D Donadio; G Leverger; M Leporrier; J Reiffers; M Janvier
Journal:  Blood       Date:  1992-05-15       Impact factor: 22.113

3.  Phase I clinical study for recombinant human granulocyte colony-stimulating factor.

Authors:  S Asano; N Shirafuji; K Watari; S Matsuda; N Uemura; R Ieki; H Kodo; F Takaku
Journal:  Behring Inst Mitt       Date:  1988-08

4.  Severe aplastic anemia (SAA): response to cyclosporin A (CyA) in vivo and in vitro.

Authors:  J Tong; A Bacigalupo; G Piaggio; O Figari; M T van Lint; D Occhini; T Lamparelli; F Gualandi; A M Marmont
Journal:  Eur J Haematol       Date:  1991-04       Impact factor: 2.997

5.  Bilineage response in refractory aplastic anemia patients following long-term administration of recombinant human granulocyte colony-stimulating factor.

Authors:  Y Sonoda; H Yashige; H Fujii; S Tsuda; T Maekawa; S Misawa; T Abe
Journal:  Eur J Haematol       Date:  1992-01       Impact factor: 2.997

6.  Granulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.

Authors:  K Ikebuchi; S C Clark; J N Ihle; L M Souza; M Ogawa
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.